Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 16/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 16/20 | 0.55 |
| ▸ | CLK3 | P49761 | 13/20 | 0.55 |
| ▸ | WNT1 | P04628 | 3/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20965770 | 0.93 | WNT1 (0.52) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18479909 | 0.92 | CLK2 (0.58) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18448687 | 0.90 | CLK2 (0.59) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL20423132 | 0.90 | CLK2 (0.49) | CLK2DYRK1ACLK3WNT1PRKCZ | |
| SCHEMBL18451733 | 0.90 | DYRK1A (0.48) | CLK2DYRK1ACLK3WNT1PRKCZ | |
| SCHEMBL18447980 | 0.90 | CLK2 (0.58) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18437201 | 0.89 | CLK2 (0.61) | CLK2DYRK1ACLK3WNT1PRKCZ | |
| SCHEMBL18441286 | 0.88 | WNT1 (0.66) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18447921 | 0.88 | CLK2 (0.55) | CLK2DYRK1ACLK3WNT1 | |
| SCHEMBL18448578 | 0.87 | CLK2 (0.58) | CLK2DYRK1ACLK3WNT1PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | claimed |
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | WNT1, WNT3A, WNT3 | CLK2 2043/4885DYRK1A 849/4885CLK3 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.